At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 29 enrolled
Drug / intervention
BI 836880drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A First-in Human Phase I, Non-randomised, Open-label, Multi-center Dose Escalation Trial of BI 836880 Administered by Repeated Intravenous Infusions in Patients With Solid Tumors.
In Brief
A Phase 1 clinical trial evaluating BI 836880 for Neoplasms. Completed, enrolled 29 participants across 3 sites in 2 countries.
Detailed Summary
This is a Phase I, non-randomized, uncontrolled, open-label, dose escalating study of BI 836880 administered intravenously. The eligible patient population will be patients with advanced solid tumours. At any time during the trial, it will not be permitted to escalate to a dose which does not fulfil the escalation with overdose control (EWOC) criterion
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms
CountriesFrance, Germany
Collaborators--
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJan 2016
First PostedFeb 2016
Primary CompletionSep 2018
Study CompletionNov 2020
TodayJul 2026
First PostedFeb 4, 2016
Enrollment StartJan 5, 2016
Primary CompletionSep 12, 2018
Study CompletionNov 4, 2020
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 10.4 years ago
Interventions
BI 836880drug
BI 836880